Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
Sponsored by AMAG Pharmaceuticals, Inc.
About this trial
Last updated 10 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 19 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Male or female patients ≥ 18 years.
- Have chronic kidney disease per K/DOQI guidelines.
- No change in EPO status during study.
- Baseline hemoglobin of ≤ 11.0 g/dl.
Exclusion Criteria
- Women who are pregnant or lactating.
- Received another investigational drug or device within 30 days.
- Recent parenteral or oral iron therapy.
- Patients with active GI bleeding or acute bleeding within 4 weeks.
- Patients that have other causes of anemia.
- Major surgery within 30 days or anticipated or planned major surgery during the study.
- Patients whose EPO status changes while on study.
- Patients with active infections.
- Recent blood transfusions.
- Patients with any known allergies to iron products.